戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 art failure hospitalization in patients with systolic heart failure.
2 e, and reduced cost of care in patients with systolic heart failure.
3 trial was conducted of 6800 outpatients with systolic heart failure.
4  prognostic implications among patients with systolic heart failure.
5 nd is at least as common in the community as systolic heart failure.
6 urvival benefit in patients with nonischemic systolic heart failure.
7 stination therapy in patients with end-stage systolic heart failure.
8 ted cardiomyopathy (DCM), a leading cause of systolic heart failure.
9 d to reduce hospitalization and mortality in systolic heart failure.
10  that is in clinical trials for treatment of systolic heart failure.
11 ailability and muscle power in patients with systolic heart failure.
12 iorespiratory fitness (CRF) in patients with systolic heart failure.
13 ure in patients with decompensated end-stage systolic heart failure.
14 ure in patients with decompensated end-stage systolic heart failure.
15 reasingly prevalent in patients with chronic systolic heart failure.
16 vabradine reduces afterload of patients with systolic heart failure.
17 ct of isolated HR reduction in patients with systolic heart failure.
18 ardiac contractility is a central feature of systolic heart failure.
19 ivator, omecamtiv mecarbil, in patients with systolic heart failure.
20 n may provide a new therapeutic approach for systolic heart failure.
21 rral cohort representing a broad spectrum of systolic heart failure.
22 stic and prognostic utility in patients with systolic heart failure.
23 ing is the principal cause of progression of systolic heart failure.
24 in children and adolescents with symptomatic systolic heart failure.
25  having symptoms that could be attributed to systolic heart failure.
26 emerged as an important therapy for advanced systolic heart failure.
27 igh morbidity and mortality in patients with systolic heart failure(2,3) or have shown a very modest
28    We prospectively recruited 30 adults with systolic heart failure +/-21 days from LVAD implantation
29 rom 39 patients with decompensated end-stage systolic heart failure (92% male), aged 56 +/- 13 years.
30                  Among patients with chronic systolic heart failure, a modest increase in peak VO(2)
31 daily with placebo in patients with ischemic systolic heart failure according to baseline high sensit
32 pathogenic variant status and associate with systolic heart failure across various clinical settings.
33       Peripartum cardiomyopathy is a form of systolic heart failure affecting young women toward the
34                            Identification of systolic heart failure among patients presenting to the
35                             In patients with systolic heart failure and a QRS duration of less than 1
36                                Patients with systolic heart failure and anemia have worse symptoms, f
37 n alfa on clinical outcomes in patients with systolic heart failure and anemia.
38                    Fifty-three patients with systolic heart failure and bundle-branch block underwent
39 valuated and is used in select patients with systolic heart failure and chronic stable angina without
40 use of escitalopram in patients with chronic systolic heart failure and depression.
41 ital heart disease patients with symptomatic systolic heart failure and electrical dyssynchrony, CRT
42          Among LVAD recipients with advanced systolic heart failure and high baseline prevalence of m
43  is widely used for the treatment of chronic systolic heart failure and hypertension, and has been de
44                  We studied 11 patients with systolic heart failure and left bundle-branch block sche
45 of ventricular systole are characteristic of systolic heart failure and might be improved by a new th
46 PHASIS-HF trial (Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms).
47                             In patients with systolic heart failure and mild symptoms, eplerenone red
48 -blind trial, we assigned 2278 patients with systolic heart failure and mild-to-moderate anemia (hemo
49 t improve clinical outcomes in patients with systolic heart failure and mild-to-moderate anemia.
50 ion (CRT) prolongs survival in patients with systolic heart failure and QRS prolongation.
51 uired to be monitored for the development of systolic heart failure and reduction of left ventricular
52 iews data from randomized clinical trials in systolic heart failure and the interactions between base
53 eatment for patients with moderate to severe systolic heart failure and ventricular dyssynchrony.
54 ents that clinically have both diastolic and systolic heart failure and will soon become the most com
55         Background Patients with nonischemic systolic heart failure are at an increased risk of sudde
56                       Patients with advanced systolic heart failure are at risk of unintentional weig
57 ined ventricular tachycardia with syncope or systolic heart failure as a result of ischemic or nonisc
58 ntagonists improve outcomes in patients with systolic heart failure but may induce worsening of renal
59 om those with a depressed ejection fraction (systolic heart failure), but echocardiography can.
60 ced intracellular aggregate accumulation and systolic heart failure by 12 months.
61 an exercise training trial for patients with systolic heart failure, cardiopulmonary exercise tests w
62 brillator (ICD) in patients with symptomatic systolic heart failure caused by coronary artery disease
63 urvival benefit in patients with nonischemic systolic heart failure during a median follow-up of 5.6
64 urvival benefit in patients with nonischemic systolic heart failure during a median follow-up of 5.6
65                      Among the patients with systolic heart failure (ejection fraction </=35%) random
66 m coenzyme Q in 1,191 patients with ischemic systolic heart failure enrolled in CORONA (Controlled Ro
67 y profile) in patients with mild symptoms of systolic heart failure, even in those already receiving
68 s with New York Heart Association class I/II systolic heart failure exhibit left ventricular (LV) rev
69 61 children and adolescents with symptomatic systolic heart failure from 26 US centers.
70 h greater proportional representation in the systolic heart failure group; all 12 SNPs were confirmed
71 proved systolic function in a sheep model of systolic heart failure (heart failure with reduced eject
72                           Common or sporadic systolic heart failure (heart failure) is the clinical s
73 ished adjunctive treatment for patients with systolic heart failure (HF) and ventricular dyssynchrony
74 ng at night ("sleep apnea") in patients with systolic heart failure (HF) have failed to improve progn
75                    Patients with nonischemic systolic heart failure (HF) have increased risk of sudde
76           Exercise training in patients with systolic heart failure (HF) is an accepted adjunct to an
77 ls present in the setting of chronic, stable systolic heart failure (HF) is unclear.
78 ommend digoxin for patients with symptomatic systolic heart failure (HF) receiving optimal medical th
79 remodeling associated with the transition to systolic heart failure (HF) were examined in the spontan
80                                Patients with systolic heart failure (HF) who develop secondary pulmon
81         Recent reports suggest that in early systolic heart failure (HF), there is an impaired natriu
82  recovery after exercise among patients with systolic heart failure (HF).
83 ss disease severity in patients with chronic systolic heart failure (HF).
84 parameter that potently predicts outcomes in systolic heart failure (HF).
85 nical outcomes in patients hospitalized with systolic heart failure (HF).
86                 In patients with nonischemic systolic heart failure, ICD implantation did not provide
87 tractile failure during cardiac ischemia and systolic heart failure, in part due to decreased excitat
88                        These models included systolic heart failure induced by pressure overload, dia
89                                     Advanced systolic heart failure is associated with myocardial and
90  defibrillators in drug abusers with chronic systolic heart failure is both sensitive and controversi
91                                              Systolic heart failure is characterized by ventricular d
92  transplantation as soon as the diagnosis of systolic heart failure is established.
93 and other procedures in patients with severe systolic heart failure is unclear.
94 trolled trial, 556 patients with symptomatic systolic heart failure (left ventricular ejection fracti
95 fication of mRNA decapping as a mechanism of systolic heart failure may open the way to the developme
96 RVEF) can identify patients with nonischemic systolic heart failure more likely to benefit from ICD i
97 CD implantation in patients with symptomatic systolic heart failure not caused by coronary artery dis
98                             In patients with systolic heart failure not caused by ischemic heart dise
99                            Patients with non-systolic heart failure (NS-CHF) had significantly lower
100  echocardiographic analysis in patients with systolic heart failure obtained from a variety of invest
101 efibrillators] in Patients With Non-Ischemic Systolic Heart Failure on Mortality) did not demonstrate
102 illators [ICDs] in Patients With Nonischemic Systolic Heart Failure on Mortality) found that primary-
103 illators [ICDs] in Patients With Nonischemic Systolic Heart Failure on Mortality) found that primary-
104 fficacy of ICDs in Patients With Nonischemic Systolic Heart Failure on Mortality) trial.
105 ficacy of ICDs in Patients With Non-Ischemic Systolic Heart Failure on Mortality), adding 4 years of
106 fficacy of ICDs in Patients with Nonischemic Systolic Heart Failure on Mortality), patients with noni
107 ficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality).
108 ardiomyopathy, defined as a new diagnosis of systolic heart failure or a left ventricular ejection fr
109            METHODS AND We studied 2231 adult systolic heart failure patients (27% of whom were women)
110 ducted a randomized, controlled trial of 223 systolic heart failure patients and compared the effects
111                                        Among systolic heart failure patients referred for PET/FDG, ea
112      In a multicenter cohort of 1513 chronic systolic heart failure patients, we measured a contempor
113 ment of patients with moderately symptomatic systolic heart failure, patients experienced thromboembo
114 ure on Mortality), patients with nonischemic systolic heart failure randomized to ICD or control unde
115                                           In systolic heart failure, reduction in relatively high hea
116 ansplantation in ESRD patients with advanced systolic heart failure results in an increase in LVEF, i
117 ontrols and 1,117 Caucasian individuals with systolic heart failure revealed 12 SNPs in the cardiovas
118 gnificantly lower BNP levels than those with systolic heart failure (S-CHF) (413 pg/ml vs. 821 pg/ml,
119 e retrospective cohort had 664 patients with systolic heart failure (SHF) and 399 patients with diast
120 ol group of 35 subjects and 60 patients with systolic heart failure (SHF) were included for compariso
121 uretic peptide (BNP) levels in patients with systolic heart failure (SHF).
122 h carries similar morbidity and mortality to systolic heart failure (SHF).
123                          Among patients with systolic heart failure, sinus rhythm, and heart rate >/=
124 enefit of prophylactic ICDs in patients with systolic heart failure that is not due to coronary arter
125 ve pulmonary disease, hypertension, elderly, systolic heart failure, thyroid disease), and CHA(2)DS(2
126      In decompensated patients with advanced systolic heart failure, tissue Doppler-derived mitral E/
127                   This study used the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor
128 vabradine and outcomes in chronic HF (SHIFT [Systolic Heart Failure Treatment With the IF Inhibitor I
129 o either placebo or ivabradine in the SHIFT (Systolic Heart Failure Treatment With the If Inhibitor I
130 Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure) trial results.
131 s in a cohort of patients with non-ischaemic systolic heart failure, using data collected prior to IC
132  a compound that has been developed to treat systolic heart failure via targeting the cardiac myosin
133  prevention ICD in patients with nonischemic systolic heart failure warrants further investigation.
134 ure in patients with decompensated end-stage systolic heart failure was recently challenged, but the
135                         In 110 patients with systolic heart failure, we evaluated the correlation bet
136     In DANISH, 556 patients with nonischemic systolic heart failure were randomized to receive an ICD
137 DANISH trial, 1116 patients with nonischemic systolic heart failure were randomized to receive an ICD
138                    Patients hospitalized for systolic heart failure were randomly assigned to HNC or
139 au patterns may be observed in patients with systolic heart failure who cannot further increase .Q at
140 tors (PROSe-ICD) enrolled 1189 patients with systolic heart failure who underwent ICD implantation fo
141             Twelve male patients with stable systolic heart failure whose initial polysomnograms show
142 ntolerance, they progressively switch toward systolic heart failure with 100% KO mice dying after 13
143 ) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex.
144 ose (LDL concentration) for the treatment of systolic heart failure with statin therapy.
145 easingly utilized for patients with advanced systolic heart failure, women continue to represent a sm

 
Page Top